Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omiganan - Cutanea Life Sciences

Drug Profile

Omiganan - Cutanea Life Sciences

Alternative Names: CLS-001; CPI-226; MBI-226; MBI-594AN; MX-226; MX-594AN; Omiganan pentachloride; Omiganan pentahydrochloride; Omiganan pentahydrochloride 1% gel; Omigard

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MIGENIX
  • Developer Cadence Pharmaceuticals; Carrus Capital Corporation; Cutanea Life Sciences
  • Class Antibacterials; Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Phase III Rosacea
  • Phase II Acne vulgaris; Atopic dermatitis; Condylomata acuminata; Seborrhoeic dermatitis; Vulvar intraepithelial neoplasia
  • No development reported Dermatitis
  • Discontinued Catheter infections

Most Recent Events

  • 29 Nov 2022 Omiganan is still in phase-II trials for Seborrhoeic dermatitis in Netherlands (Topical) (EudraCT2017-003106-41)
  • 28 Mar 2020 No recent reports of development identified for phase-I development in Dermatitis(Combination therapy, Monotherapy, In volunteers) in Netherlands (Topical, Gel)
  • 05 Oct 2018 Cutanea Life Sciences plans a phase II trial for Seborrheic dermatitis (In adults, In the elderly) in Netherlands (Topical) (NCT03688971)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top